

# Regulation of Liver and Adipose Tissue Lipogenesis in Human Obesity


Ludger Scheja

NuGO Week 2011, Wageningen



Universitätsklinikum  
Hamburg-Eppendorf

# De Novo Lipogenesis (DNL) Pathway



**FASN:** fatty acid synthase

**SCD:** stearoyl CoA desaturase

**ELOVL6;** fatty acid elongase-6

# ***De Novo Lipogenesis (DNL) in Mice***

- Mice efficiently convert dietary carbohydrates to fatty acids
- **Liver DNL** is up-regulated in obese mice; mechanisms:
  - Hyperinsulinemia (SREBP1c)
  - Increased glucose flux (ChREBP)
- DNL-linked fatty acid elongase ELOVL6 has adverse metabolic effects  
(Matsuzaka et al. 2007, Nat Med 13:1193)
- **Adipose Tissue DNL** is down-regulated in obesity
- DNL-derived palmitoleic acid (C16:1) counteracts insulin resistance (Cao et al. 2008, Cell 134:933)

# ***De Novo Lipogenesis (DNL) in Humans***

- Dietary carbohydrates is converted to fatty acids by fatty acid synthase (FASN)
- Obese subjects have a higher rate of hepatic DNL than lean subjects
- FASN mRNA is down-regulated in adipose tissue in obesity
- Common polymorphisms in FASN gene are associated with BMI

# Aim of the Study


Characterize the regulation of DNL in human obesity

- Expression of biosynthetic enzymes
- DNL-derived fatty acids
- Link to metabolic disease parameters


# Study Cohort

- Tissue bank, Dept. of Surgery, University of Ulm  
(Anna Wolf, Uwe Knippschild)
- Surgery patients: morbid obesity > non-metastatic cancer > other cases (no liver disease)
- Patients with liver and adipose tissue samples: n=165

# Study Cohort: HOMA-IR





# Liver FASN Expression versus BMI






# Liver FASN Expression versus BMI




# Liver FASN Expression versus HOMA-IR, Liver TG, CRP




# Liver FASN Expression versus HOMA-IR, Liver TG, CRP




## HOMA-IR



## Liver TG




# Liver FASN Expression versus HOMA-IR, Liver TG, CRP



# Experimental Subgroups


- Gender-matched, (partially) age-matched, n=20, controls (lean and overweight), obese, obese+T2D (type 2 diabetes)



T-Test vs. controls, \* p< 0.05, \*\* p< 0.001

# Experimental Subgroups


- Gender-matched, (partially) age-matched, n=20, controls (lean and overweight), obese, obese+T2D (type 2 diabetes)



T-Test vs. controls, \* p < 0.05, \*\* p < 0.001


# Experimental Subgroups

- Gender-matched, (partially) age-matched, n=20, controls (lean and overweight), obese, obese+T2D (type 2 diabetes)



T-Test vs. controls, \* p< 0.05, \*\* p< 0.001


# Liver DNL Gene Expression



T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$




# Liver DNL Gene Expression




T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$

# Liver DNL Gene Expression




T-Test vs. controls, \* p < 0.05, \*\* p < 0.001

# Visceral Adipose Tissue (VAT) Lipogenic Gene Expression




T-Test vs. controls, \* p< 0.05, \*\* p< 0.001

# Visceral Adipose Tissue (VAT) Lipogenic Gene Expression



T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$


# Visceral Adipose Tissue (VAT) Lipogenic Gene Expression





T-Test vs. controls, \* p < 0.05, \*\* p < 0.001

# VAT Westernblots

- FASN, upstream DNL proteins





# VAT Westernblots



1-way ANOVA: Repeated T-TEST  
 Tukey-Kramer test to correct for multiple comparison

# VAT Westernblots



1-way ANOVA: Repeated T-TEST  
Tukey-Kramer test to correct for multiple comparison




# Palmitoleate (C16:1) in Mouse Adipose Tissue

- Biosynthetic capacity DNL severely impaired in obese adipose tissue => is this reflected in fatty acid patterns ?

T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$

# Palmitoleate (C16:1) in Mouse Adipose Tissue


- Biosynthetic capacity DNL severely impaired in obese adipose tissue => is this reflected in fatty acid patterns ?




T-Test vs. controls, \* p< 0.05, \*\* p< 0.001

# DNL-Derived Fatty Acids in Human VAT


**Palmitic Acid  
C16:0**



**Palmitoleic Acid  
C16:1n-7**



**Vaccenic Acid  
C18:1n-7**



T-Test vs. controls, \* p < 0.05

# Summary and Conclusions – Human Liver

- The DNL pathway is profoundly induced in liver of (morbidly) obese humans

# Summary and Conclusions – Human Liver

- The DNL pathway is profoundly induced in livers of (morbidly) obese humans
- Liver FASN expression correlates strongly with HOMA-IR, indicating a link to liver insulin resistance/hyperinsulinemia

# Summary and Conclusions – Human Liver

- The DNL pathway is profoundly induced in livers of (morbidly) obese humans
- Liver FASN expression correlates strongly with HOMA-IR, indicating a link to liver insulin resistance/hyperinsulinemia
- The induction of liver ELOVL6 may support insulin resistance by increasing synthesis of stearic acid (C18:0), as described in mice (Matsuzaka et al. 2007, Nat Med 13:1193)

# Summary and Conclusions: Human VAT

- Except for SCD, the DNL pathway is strongly suppressed in (diabetic) obese humans

# Summary and Conclusions: Human VAT

- Except for SCD, the DNL pathway is strongly suppressed in (diabetic) obese humans
- Down-regulation of GLUT4 protein in insulin resistant subjects is consistent with a crucial role of GLUT4 for whole body insulin sensitivity (Abel et al., 2001, Nature 409:729)



# Summary and Conclusions: Human VAT

- Except for SCD, the DNL pathway is strongly suppressed in (diabetic) obese humans
- Down-regulation of GLUT4 protein in insulin resistant subjects is consistent with a crucial role of GLUT4 for whole body insulin sensitivity (Abel et al., 2001, Nature 409:729)
- Palmitoleate (C16:1) does not drop in obesity (compensation by liver)

# Ongoing/Future Work

- Fatty acid profiling in liver and plasma
- Gene expression changes in adipose tissue after weight loss
- Study liver pathology
- Lipidomics (DNL biomarker)

# Acknowledgements

## **Department of Surgery, Ulm**

Uwe Knippschild

Anna Wolf

## **Mount Sinai School of Medicine, New York**

Thomas Scherer

Christoph Büttner

## **Department of Surgery, Maastricht**

Sander Rensen

## **Dept. of Biochemistry, Hamburg**


Leah Eissing

Klaus Tödter


Jörg Heeren

# Appendix


# Study Cohort: Liver Steatosis



# Study Cohort: CRP




# Liver FASN Westernblot



n > 8, T-Test vs. controls, \* p < 0.05, \*\* p < 0.001


# Correlation VAT GLUT4 - HOMA-IR





# Mouse Adipose Tissue Macrophage Infiltration


- In mice, obesity is accompanied by massive macrophage infiltration in white adipose tissue



Scheja et al., 2011, BBRC 407:288


T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$

# Expression of Macrophage Markers in Human VAT



T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$


# Inflammatory Cytokine Expression in Human VAT




T-Test vs. controls, \*  $p < 0.05$ , \*\*  $p < 0.001$

# Adipose Tissue Gene Expression After Weight Loss

- Bariatric surgery, performed at Maastricht University Hospital
- Subcutaneous adipose tissue samples before and after intervention




# Liver Transcription Factor Expression



# Title

Matsuzaka et al., Nature Medicine 13, (2007) **Crucial role of a long-chain fatty acid elongase, Elov16, in obesity-induced insulin resistance**

## Elov16 knockout



## Elov16 forced expression

